Featuring perspectives from Dr Christopher Lieu, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring perspectives from Dr Daneng Li, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring perspectives from Dr Kathleen N Moore, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring perspectives from Dr Stephen T Oh, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics:

• Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment
  • Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00)
• EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer
  • Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023;Abstract 188O. (5:50)
• Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer
  • Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024;Abstract 1027. (9:43)

CME information and select publications

Featuring perspectives from Dr Harry Paul Erba, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring perspectives from Dr Edward B Garon, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring perspectives from Dr Heather Wakelee, including the following topics:

• Introduction (0:00)
• Cases: A man in his late 50s with metastatic carcinoma of the lung, no actionable genomic alteration (AGA), PD-L1-negative, and a man in his early 60s with metastatic squamous cell carcinoma of the lung, PD-L1-negative — Brian P Mulherin, MD and Taral Patel, MD (8:08)
• Case: A man in his late 60s presenting with metastatic adenocarcinoma of the lung, multiple bone metastases, no AGA; PD-L1 20%; enrolled on ECOG-EA5163 — Priya Rudolph, MD, PhD (21:45)
• Current and Emerging Immunotherapeutic Strategies for Metastatic Non-Small Cell Lung Cancer (mNSCLC) (30:55)
• Case: An African American man in his early 60s with 6.2-cm squamous cell carcinoma of right upper lung receives neoadjuvant treatment as per CheckMate 816 — Dr Rudolph (39:16)
• Case: A man in his late 60s with pT2aN0 invasive adenocarcinoma of the right lower lung, no AGA; PD-L1 5% — Zanetta S Lamar, MD (44:57)
• Antibody-Drug Conjugates and Other Management Approaches for mNSCLC without AGAs (48:51)
• Case: A woman in her early 60s diagnosed in 2014 with metastatic adenocarcinoma of the lung treated on ECOG 5508 (carboplatin/paclitaxel/bevacizumab) receives nivolumab on disease progression — Dr Rudolph (56:35)

CME information and select publications

Featuring perspectives from Dr Priyanka Sharma and Dr Sara M Tolaney, including the following topics:

• Introduction: Metastatic Triple-Negative Breast Cancer (mTNBC) — The Patient Perspective (0:00)
• Selection and Sequencing of Antibody-Drug Conjugates (5:09)
• Dosing and Tolerability of Sacituzumab Govitecan; Use of Anthracyclines (14:39)
• Case: A woman in her early 60s with relapsed TNBC (HER2 2+) who experiences disease progression on T-DXd (Grade 2 interstitial lung disease) and receives sacituzumab govitecan — Shaachi Gupta, MD, MPH (22:04)
• Discussing Palliative and End-of-Life Care (32:40)
• PARP Inhibitors for TNBC with Somatic versus Germline Mutations; Cytopenias with PARP Inhibitors (37:53)
• The “Art of Oncology” — Building Trust with Patients and Family Members (45:05)
• Case: A woman in her mid 60s with recurrent TNBC with extensive chest wall involvement — Dr Gupta (48:44)
• Case: A man in his mid 40s with multiregimen-refractory AR-positive TNBC with an ERBB2 exon 20 insertion mutation — Dr Gupta (52:53)

CME information and select publications

Featuring perspectives from Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile M Shammo, including the following topics:

Introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) and the General Medical Oncologist

• Diagnosis of and myths and misperceptions about PNH (0:00)

Overview — Biology and Pathophysiology

• Role of complement activation in PNH; classification and clinical presentation (7:00)
• PNH treatments and their complement targets (21:37)

Current Management Approaches

• Mechanistic similarities and differences between crovalimab and other available C5 inhibitors; potential practical advantages of crovalimab (24:56)
• Timing for initiation of treatment for PNH (32:08)
• Management of clinically significant extravascular hemolysis and residual anemia in patients with PNH receiving C5 inhibitor therapy (43:08)
• Risk of evolution to aplastic anemia or myeloid malignancy (45:54)
• Clinical trial database establishing the efficacy and safety of the C5 complement inhibitors eculizumab and ravulizumab for PNH (48:47)
• Activity and safety of and clinical experience with crovalimab (53:03)
• Monitoring and management of PNH in pregnant patients (58:37)

Case Presentations

• Case: A woman in her early 30s who receives a new diagnosis of classical PNH with symptomatic anemia — Dr Gerber (1:03:44)
• Case: A man in his early 30s with PNH initially treated with eculizumab who is transitioned to ravulizumab — Dr Koprivnikar (1:17:32)
• Case: A woman in her early 50s with a remote history of aplastic anemia — Dr Gerber (1:32:24)
• Case: A woman in her late 20s with PNH receiving active C5 inhibitor therapy who wishes to discuss alternative treatment options — Dr Koprivnikar (1:38:00)

CME information and select publications

Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal Hemoglobinuria — Jamile M Shammo, MD

CME information and select publications